Abstract:e20074 Background: It is unclear about the clinical outcome of the combination of icotinib and rh-endostatin (Endostar) in treating advanced non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations. This single-arm pilot study aims to investigate the preliminary efficacy and safety of the combination therapy for those patients. Methods: Patients with histologically confirmed nonsquamous advanced NSCLC who had exon 19 exon del or L858R were included. All patients received icotinib (125 mg po TID) plus rh-endostatin (15 mg civ for ten days, every 3 weeks) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) at 24 weeks, and secondary endpoint is safety profile. In addition, exploratory evaluation was performed using dynamic contrast enhanced MRI (DCE-MRI) to analyse the tumor vascular permeability parameter, Ktrans. Results: 10 patients have been enrolled. The median age was 60 years old, with 7 female and 3 male patients. There were 6 patients with exon 19 del, 3 patients with L858R mutation, and 1 patient with L858R and S768I muation. The preliminary results showed the clinical ORR at 24 weeks was 60% (1 complete resonse, 5 partial responses, and 4 stable diseases) and a mean reduction in tumor size of 32.5%. Compared with baseline, there was 52.4% and 7.5% increase in patients who obtained ORR and SD as their best response with mean Ktrans of 0.22 and 0.40, respectively. The dynamic changes of Ktrans were consistent with clinical outcome of tumor responses. In ORR group, the tumor Ktransdropped as early as seven days after the therapy, while it remained stable in SD group. The overall tolerability of the combination was good, as there were no toxicities of CTC-AE 4.0 grade 3 or greater. Conclusions: The combination of icotinib and rh-endostatin was effective and safe. Serial Ktrans derived from DCE-MRI could be used as a non-invasive imaging biomarker to prodict the tumor response after treatment, optimize the regimen and facilitate the identification of the best patient population who may potentially benefit from this combination regimen. Clinical trial information: NCT02375022.

Icotinib Plus Gemcitabine for Metastatic Pancreatic Cancer: A Case Report

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

The Synergy of Gene Targeting Drug Icaritin Soft Capsule with Immunomodulator and TACE Brings New Hope for Drug Combination in Patients with Advanced Liver Cancer: A Case Report and Literature Review

Metastatic Ovarian Tumor from Pancreatic Cancer Treated with Combined Immunotherapy: A Case Report

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Combination Therapy of Apatinib with Icotinib for Primary Acquired Icotinib Resistance in Patients with Advanced Pulmonary Adenocarcinoma with EGFR Mutation.

The Efficacy And Safety Of Icotinib In Patients With Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

A Marked Response to Icotinib in a Patient with Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation: A Case Report.

Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Effective Treatment with Icotinib in Lung Adenocarcinoma with EGFR and ALK Co-Alterations and Brain Metastasis

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

Erlotinib in Combination with Chemotherapy for Patients with Advanced Pancreatic Cancer

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma

Pemetrexed-carboplatin with Intercalated Icotinib in the Treatment of Patient with Advanced EGFR Wild-Type Lung Adenocarcinoma

Inhibition of Sirt1 Combined with Gemcitabine Therapy for Pancreatic Carcinoma

Transarterial Infusion with Gemcitabine and Oxaliplatin for the Treatment of Unresectable Pancreatic Cancer

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Icotinib Versus Cisplatin Plus Docetaxel As Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.

Efficacy and Safety of Gemcitabine Plus Erlotinib for Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

Icotinib and Rh-Endostatin As First Line Therapy in Advanced Non Small Cell Line Cancer Patients Harboring Activating Epidermal Growth Factor Receptor Mutations.

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.